NHS to offer five-session 'precision' radiotherapy for prostate cancer

NHS England has announced that eligible men with early prostate cancer will be offered a precision form of radiotherapy known as SABR, which delivers a higher dose directly to the tumour while limiting damage to surrounding healthy tissue. The move represents one of the most significant changes to routine prostate cancer treatment in years, promising shorter, more convenient courses of care for thousands of patients.

Announced on 10 June, the treatment uses focused beams of radiation directed from multiple angles. It can typically be completed in five sessions over a fortnight, compared with at least 20 sessions for conventional radiotherapy, reducing both hospital visits and side-effects. For many men, that means less time travelling to and from hospital, fewer days disrupted by treatment and a faster return to ordinary life.

Stereotactic ablative body radiotherapy, to give SABR its full name, has been used for some cancers for several years, but its extension to early prostate cancer as a standard option marks a notable step. The technique relies on advanced imaging and precise targeting to concentrate the radiation dose where it is needed, sparing nearby organs such as the bladder and bowel.

Thousands could benefit

Around 17,500 men are diagnosed with low or intermediate-risk prostate cancer in England each year, with modelling suggesting roughly 3,500 may choose the new option. The technique is set to be available at all 48 radiotherapy centres in England, with the first sites beginning to offer it within days, giving the rollout a genuinely national reach from the outset.

Prostate cancer is the most common cancer in men in the UK, and outcomes for those diagnosed early are generally very good. The appeal of SABR lies not in dramatically higher cure rates, which are already high for early-stage disease, but in delivering equivalent results with far fewer treatment sessions and a comparable or improved side-effect profile.

“This technology lets us focus a powerful and precise beam directly onto cancer, limiting damage to healthy cells.”

— Professor Peter Johnson, NHS national clinical director for cancer

How it compares with conventional treatment

Traditional external beam radiotherapy for prostate cancer is usually spread across several weeks, with patients attending hospital on most weekdays for a single daily session. While effective, that schedule can be burdensome, particularly for older patients, those who live far from a treatment centre or those who must arrange transport and time away from work or caring responsibilities.

By compressing the course into five sessions, SABR reduces the cumulative disruption substantially. Clinicians stress that not every patient will be suitable, and that the decision will depend on the characteristics of the individual tumour and the patient's overall health, but for those who are eligible the benefits in convenience and quality of life can be considerable.

• SABR delivers radiotherapy in five sessions rather than at least 20
• It targets the tumour precisely, sparing surrounding healthy tissue
• Around 17,500 men are diagnosed with low or intermediate-risk prostate cancer in England each year
• Modelling suggests roughly 3,500 patients a year may choose the option
• The treatment will be available at all 48 radiotherapy centres in England

Background and wider significance

The announcement fits within a broader NHS drive to adopt techniques that improve efficiency as well as outcomes. With cancer services under sustained pressure and waiting times a persistent concern, treatments that achieve the same results in fewer appointments offer a rare combination of clinical and operational benefit. Officials said the rollout could free up around 50,000 appointments a year, capacity that can be redirected to other patients.

Trials are under way to assess whether the approach could also help patients with higher-risk disease, potentially widening the pool of people who could benefit in future. If those studies prove positive, the share of prostate cancer patients treated with shorter, more targeted courses could grow well beyond the current early-stage cohort.

“Shorter courses that achieve the same outcomes are good for patients and good for an overstretched service.”

— An NHS cancer specialist

What it means for patients

For men newly diagnosed with early prostate cancer, the immediate change is the prospect of a more convenient treatment pathway, discussed and decided with their clinical team. Patients are encouraged to talk through the options, including active surveillance, surgery and different forms of radiotherapy, to determine the approach best suited to their circumstances. As the rollout beds in across all centres, SABR is expected to become a familiar part of that conversation, marking a quiet but meaningful improvement in how one of the country's most common cancers is treated.